Print
Email
Print Edition StoriesThursday, May 29, 2008
Haemonetics lands Octapharma as plasma collection client
By Mass High Tech Staff
Haemonetics Corp. of Braintree has entered into a multi-year supply contract with Octapharma AG naming the Swiss company as its preferred provider of plasma collection technology in the United States.
Under the agreement, Octapharma will use Haemonetics’ technology to separate plasma from donor blood at its U.S. plasma collection centers. The plasma provides proteins, including albumin, clotting factors and intravenous immunoglobulin, for use in drug development and for therapeutic purposes.
No financial details of the deal were released.
Octapharma is the largest privately owned plasma products company in the world, according to officials. The company owns five facilities for separating out the components of plasma in Austria, France, Sweden, Germany and Mexico.
Haemonetics reported a profit of $52 million on revenue of $516.4 million for 2007.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
